These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 33677351)
1. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates. Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351 [TBL] [Abstract][Full Text] [Related]
2. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581 [TBL] [Abstract][Full Text] [Related]
3. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969 [TBL] [Abstract][Full Text] [Related]
4. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337 [TBL] [Abstract][Full Text] [Related]
5. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Wang Y; Fan S; Zhong W; Zhou X; Li S Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298 [TBL] [Abstract][Full Text] [Related]
7. Effect of attachment site on stability of cleavable antibody drug conjugates. Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134 [TBL] [Abstract][Full Text] [Related]
8. HER2-targeted antibody drug conjugates for ovarian cancer therapy. Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865 [TBL] [Abstract][Full Text] [Related]
9. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559 [TBL] [Abstract][Full Text] [Related]
10. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698 [TBL] [Abstract][Full Text] [Related]
11. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333 [TBL] [Abstract][Full Text] [Related]
12. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875 [TBL] [Abstract][Full Text] [Related]
13. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821 [TBL] [Abstract][Full Text] [Related]
14. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798 [TBL] [Abstract][Full Text] [Related]
15. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587 [TBL] [Abstract][Full Text] [Related]
16. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591 [TBL] [Abstract][Full Text] [Related]
17. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573 [TBL] [Abstract][Full Text] [Related]
18. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436 [TBL] [Abstract][Full Text] [Related]
19. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E. Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D Front Immunol; 2018; 9():1799. PubMed ID: 30123222 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]